What does Neumora Therapeutics, Inc. do?
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor…
What is Neumora Therapeutics, Inc.'s P/E and P/B ratio?
Neumora Therapeutics, Inc. has a P/E ratio of -0.3 and a P/B ratio of 1.71.
What is Neumora Therapeutics, Inc.'s debt-to-equity ratio?
Neumora Therapeutics, Inc. has a debt-to-equity ratio of 1.20.
How much does Neumora Therapeutics, Inc. owe compared with what it owns?
Neumora Therapeutics, Inc. owes $0.64 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Neumora Therapeutics, Inc.'s Positivity rank?
Neumora Therapeutics, Inc. is ranked #1,775 of 6,774 companies globally and #440 of 4,000 in United States on PositoAI, with a Positivity Score of 22,315.
Does Neumora Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Neumora Therapeutics, Inc..
Where can I read the latest news about Neumora Therapeutics, Inc.?
Recent headlines about Neumora Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Neumora Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Neumora Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.